Cancer | pharmaphorum

Thursday 24 September 2026

Cancer

News

Nearly 300 gene and cell therapies in development - report

Nearly 300 gene and cell therapies in development - report

Pharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting review by the FDA, according to a new report from US trade body PhRMA

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Oncology

Anthill_webinar_holding_slide-04_12_2018-ONE-NEW

Sponsored

Cancer, genomics and personalised medicine: Modelling oncolo...

Overview

News

NHS funds BMS' Opdivo to prevent skin cancer returning

NHS funds BMS' Opdivo to prevent skin cancer returning

NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year

News

EU approves Kyowa Kirin's drug for rare lymphoma

EU approves Kyowa Kirin's drug for rare lymphoma

The European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma.

News

Bayer/Loxo drug approved in cancers with certain mutation

Bayer/Loxo drug approved in cancers with certain mutation

The FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific genetic feature, or biomarker.

News

Cancer-cells-16-9

NHS lags best performers in cancer care - report

The performance of NHS cancer services in England is lagging behind those of comparable countries, according to a new report.